These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 27987642)

  • 1. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
    Woods B; Revill P; Sculpher M; Claxton K
    Value Health; 2016 Dec; 19(8):929-935. PubMed ID: 27987642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds.
    Robinson LA; Hammitt JK; Chang AY; Resch S
    Health Policy Plan; 2017 Feb; 32(1):141-145. PubMed ID: 27452949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
    Ochalek J; Lomas J
    Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.
    Pichon-Riviere A; Drummond M; Palacios A; Garcia-Marti S; Augustovski F
    Lancet Glob Health; 2023 Jun; 11(6):e833-e842. PubMed ID: 37202020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies.
    Leech AA; Kim DD; Cohen JT; Neumann PJ
    Value Health; 2018 Jul; 21(7):759-761. PubMed ID: 30005746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of treating paediatric cancer in low-income and middle-income countries: a case-study approach using acute lymphocytic leukaemia in Brazil and Burkitt lymphoma in Malawi.
    Bhakta N; Martiniuk AL; Gupta S; Howard SC
    Arch Dis Child; 2013 Feb; 98(2):155-60. PubMed ID: 23201550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating a cost-effectiveness threshold for health care decision-making in South Africa.
    Edoka IP; Stacey NK
    Health Policy Plan; 2020 Jun; 35(5):546-555. PubMed ID: 32125375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review.
    Kazibwe J; Gheorghe A; Wilson D; Ruiz F; Chalkidou K; Chi YL
    Value Health; 2022 Mar; 25(3):385-389. PubMed ID: 35227450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries.
    Vallejo-Torres L; García-Lorenzo B; Edney LC; Stadhouders N; Edoka I; Castilla-Rodríguez I; García-Pérez L; Linertová R; Valcárcel-Nazco C; Karnon J
    Appl Health Econ Health Policy; 2022 May; 20(3):337-349. PubMed ID: 34964092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guide posts for investment in primary health care and projected resource needs in 67 low-income and middle-income countries: a modelling study.
    Stenberg K; Hanssen O; Bertram M; Brindley C; Meshreky A; Barkley S; Tan-Torres Edejer T
    Lancet Glob Health; 2019 Nov; 7(11):e1500-e1510. PubMed ID: 31564629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of Demand-Side Methods of Estimating the Societal Monetary Value of Health Gain.
    Gloria MAJ; Thavorncharoensap M; Chaikledkaew U; Youngkong S; Thakkinstian A; Culyer AJ
    Value Health; 2021 Oct; 24(10):1423-1434. PubMed ID: 34593165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thresholds for the cost-effectiveness of interventions: alternative approaches.
    Marseille E; Larson B; Kazi DS; Kahn JG; Rosen S
    Bull World Health Organ; 2015 Feb; 93(2):118-24. PubMed ID: 25883405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of a statistical life in road safety: a benefit-transfer function with risk-analysis guidance based on developing country data.
    Milligan C; Kopp A; Dahdah S; Montufar J
    Accid Anal Prev; 2014 Oct; 71():236-47. PubMed ID: 24952315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?
    Kovács S; Németh B; Erdősi D; Brodszky V; Boncz I; Kaló Z; Zemplényi A
    Appl Health Econ Health Policy; 2022 May; 20(3):291-303. PubMed ID: 35041177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Framework for developing cost-effectiveness analysis threshold: the case of Egypt.
    Fasseeh AN; Korra N; Elezbawy B; Sedrak AS; Gamal M; Eldessouki R; Eldebeiky M; George M; Seyam A; Abourawash A; Khalifa AY; Shaheen M; Abaza S; Kaló Z
    J Egypt Public Health Assoc; 2024 Jun; 99(1):12. PubMed ID: 38825614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Informing a cost-effectiveness threshold for Saudi Arabia.
    Al-Jedai AH; Lomas J; Almudaiheem HY; Al-Ruthia YSH; Alghamdi S; Awad N; Alghamdi A; Alowairdhi MA; Alabdulkarim H; Almadi M; Bunyan RF; Ochalek J
    J Med Econ; 2023; 26(1):128-138. PubMed ID: 36576804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
    Vallejo-Torres L; García-Lorenzo B; Castilla I; Valcárcel-Nazco C; García-Pérez L; Linertová R; Polentinos-Castro E; Serrano-Aguilar P
    Value Health; 2016; 19(5):558-66. PubMed ID: 27565273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries.
    Global Burden of Disease Health Financing Collaborator Network
    Lancet; 2017 May; 389(10083):2005-2030. PubMed ID: 28433260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using information on ART costs and benefits to mobilise resources - comparing different methods and contexts.
    Kinghorn A
    Afr J AIDS Res; 2019 Dec; 18(4):289-296. PubMed ID: 31779574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.